Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 24, 2014, 11:47:21 AM

Login with username, password and session length


Members
  • Total Members: 23024
  • Latest: louis80
Stats
  • Total Posts: 631729
  • Total Topics: 47824
  • Online Today: 266
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Misc news  (Read 929 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Misc news
« on: October 18, 2011, 04:23:08 PM »
Few aidsmap news   ;)

Dolutegravir is potent but twice-daily works better
The novel integrase inhibitor dolutegravir is among the most potent antiretroviral agents studied to date, but treatment-experienced individuals need to take it twice-daily in order to achieve optimal concentrations, according to findings presented yesterday at the 13th European AIDS Conference (EACS) in Belgrade.
More

Overweight patients have best gains in CD4 cell count twelve months after starting HIV therapy
Patients who would normally be classified as overweight have the biggest increases in their CD4 cell counts during the first year of HIV therapy, US investigators report in the online edition of Clinical Infectious Diseases. Immune restoration after twelve months of antiretroviral therapy was greatest among individuals with a baseline body mass index (BMI) in the range 25 to 29.9 kg/m2, which is usually described as overweight.
More

Detectable viral load in patients taking HIV therapy associated with poor control of other chronic health problems
Poor control of HIV is associated with suboptimal management of other serious health conditions, US research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes suggests.
More

Older age and immune response to CMV affect CD4 cell recovery after starting HIV therapy
Older age and a strong immune response to CMV infection adversely affect CD4 cell count recovery in patients taking antiretroviral therapy, French investigators report in the September 24th edition of AIDS.
More

New European HIV treatment guidelines expand treatment recommendations but anticipate possible drug shortages
The guidelines make no fundamental changes to the CD4 count criteria for starting antiretroviral therapy (ART), retaining 350 cells/mm3 as the threshold. But they extend the range of situations in which ART is recommended for people with higher CD4 cell counts and also include a range of situations in which ART should be 'considered'.
More

Efavirenz may be under-dosed in children
In a cohort of three to 12 year-old HIV-infected Ugandan children taking once-daily efavirenz according to 2006 World Health Organization (WHO) weight-band dosing recommendations, lower and highly variable amounts of drug entered their bloodstream compared to adults, investigators from the AntiRetroviral Research fOr Watoto (ARROW) trial team report in the advance online edition of the Journal of Acquired Immune Deficiency Syndromes.
More

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.